Syros Pharmaceuticals GAAP EPS of -$2.18 misses by $1.04, revenue of $0.4M misses by $1.6M

  • Syros Pharmaceuticals press release (NASDAQ:SYRS): Q4 GAAP EPS of -$2.18 misses by $1.04.
  • Revenue of $0.4M (as compared to negative $0.8 million in the fourth quarter of 2022) misses by $1.6M.
  • Cash, cash equivalents and marketable securities as of December 31, 2023, were $139.5 million, as compared with $202.3 million on December 31, 2022.

  • Based on its current plans, Syros believes that its existing cash, cash equivalents and marketable securities will be sufficient to fund its anticipated operating expenses and capital expenditure requirements into the second quarter of 2025, beyond pivotal Phase 3 data from the SELECT-MDS-1 trial and additional data from the randomized portion of the SELECT-AML-1 trial.

William Murphy

Related post